Specific microRNA (miRNA) signatures have been associated with different cytogenetic subtypes in acute leukemias. This finding prompted us to investigate potential associations between genetic abnormalities in multiple myeloma (MM) and singular miRNA expression profiles. Moreover, global gene expression profiling was also analyzed to find correlated miRNA gene expression and select miRNA target genes that show such correlation. For this purpose, we analyzed the expression level of 365 miRNAs and the gene expression profiling in 60 newly diagnosed MM patients, selected to represent the most relevant recurrent genetic abnormalities. Supervised analysis showed significantly deregulated miRNAs in the different cytogenetic subtypes as compared with normal PC. It is interesting to note that miR-1 and miR-133a clustered on the same chromosomal loci, were specifically overexpressed in the cases with t(14;16). The analysis of the relationship between miRNA expression and their respective target genes showed a conserved inverse correlation between several miRNAs deregulated in MM cells and CCND2 expression level. These results illustrate, for the first time, that miRNA expression pattern in MM is associated with genetic abnormalities, and that the correlation of the expression profile of miRNA and their putative mRNA targets is useful to find statistically significant protein-coding genes in MM pathogenesis associated with changes in specific miRNAs.
Introduction
The genetics of multiple myeloma (MM) has been increasingly investigated in recent years. 1, 2 Genomic data generated by high-throughput technologies in the last decade, particularly by gene expression profiling analysis, has contributed to demonstrate the enormous genetic diversity exhibited by MM [3] [4] [5] [6] and genetic classifications which incorporate genomic signatures, cyclin D expression, ploidy status and translocations of the immunoglobulin heavy-chain gene (IGH) have been proposed. Their final goal is to identify a connection between clinical behaviour of MM patients and biological features of myeloma cells to eventually individualize treatment. 5, 6 However, all these advances in the understanding of MM biology are not sufficient to explain the genesis and evolution of this malignancy. The discovery of small non-coding RNAs called microRNAs (miRNA), which control gene expression at post-transcriptional level, by degrading or repressing target mRNAs, revealed a new mechanism of gene regulation. 7, 8 It is well-known that miRNAs are involved in critical biological processes, including cellular growth and differentiation. 9 miRNA expression patterns have been explored in several hematological malignancies, such as chronic lymphocytic leukemia 10, 11 and acute myeloid leukemia; 12, 13 however, the available information in MM is limited.
14, 15 Pichiorri et al, 14 have recently investigated the possible role of miRNA in the malignant transformation of plasma cells (PCs) using 49 MM-derived cell lines and a small number of MM (16) and monoclonal gammopathies of undetermined significance (6) patients. In acute leukemias and recently in chronic lymphocytic leukemia, specific miRNA signatures have been associated with different genetic subtypes. 12, 13, [16] [17] [18] Following this approach, we wanted to search for such types of associations in MM patients. For this purpose, we have investigated the expression level of 365 miRNAs by quantitative PCR in 60 primary MM patient samples, specifically selected according to their cytogenetic features, in order to include the most relevant genetic abnormalities in MM. Although animal miRNAs were initially reported to function as translational repressors without mRNA cleavage, it is now evident that miRNAs can also induce mRNA degradation, even if the target sites do not have complete complementarity to the miRNA. 19, 20 These findings prompted us to investigate the global gene expression profiling in the same 60 patients to look for candidate mRNAs that were susceptible to miRNA induced knockdown. Our results show the presence of deregulation in miRNA expression of MM cells, which seems to be associated with cytogenetic abnormalities and correlated with geneexpression changes characteristic of MM genetic subtypes.
Materials and methods

Patients
In all, 60 patients with symptomatic newly diagnosed MM were included in the study. Five healthy controls of bone marrow (BM) samples were obtained from subjects undergoing BM harvest for allogeneic transplantation. In all the BM samples a CD138 positive PC isolation using the AutoMACs automated separation system (Miltenyi-Biotec, Auburn, CA, USA) was carried out (purity was above 90%). All patients as well as healthy donors provided written informed consent in accordance with the Helsinki Declaration, and the research ethics committee of the University Hospital of Salamanca approved the study. The total 65 samples were analyzed from both miRNAs and mRNA gene expression profiling.
Cytogenetic analysis
The selection of patients was based on cytogenetic features in order include a representative number of samples with the most relevant and recurrent genetic abnormalities. The systematic screening for genomic aberrations in our institution includes interphase fluorescence in situ hybridization studies for the detection of IGH rearrangements, RB1 and P53 deletions (Abbott Molecular/Vysis, Des Plaines, IL, USA) as previously described, 21 and 1q gains (ON 1q21/SRD 1p36, Kreatech Diagnostics, Amsterdam). Furthermore, only patients with more than 80% of PCs exhibiting genetic abnormalities were considered for the analysis, with the exception of gains on 1q and P53 deletions, which were present in a median of 77% (range, 28-100%) and 72% (range, 46-88%) of the PCs, respectively. The distribution of cytogenetic abnormalities in the 60 MM patients is summarized in Table 1 .
RNA extraction
Total RNA was extracted from normal and tumor plasma cells using miRNEasy Mini Kit (Qiagen, Valencia, CA, USA) following manufacturer's protocol. The RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent Tech, Palo Alto, CA, USA).
miRNA profiling
Complementary DNA was synthesized from total RNA using the so-called hairpin RT primer according to the TaqMan miRNA Reverse Transcription Kit (PE Applied Biosystems, Foster City, CA, USA). Reverse transcriptase reactions contained the following: 20 ng of RNA, 1.5 ml 10X RT buffer, 0.15 ml dNTP mix (100 mM total), 1 ml MultiScribe reverse transcriptase (50 U/ml), 0.19 ml AB RNase inhibitor (20 U/ml), 1 ml multiplex RT primers and 4.16 ml H 2 O (final volume 10 ml). Reactions were incubated in an Applied Biosystems GeneAmp PCR System 9700 for 30 22 The data was presented as log 10 of the relative quantity of each miRNA. 23 We used hierarchical clustering (Cluster and TreeView software) based on the average-linkage method with the centered correlation metric for unsupervised analysis. 24 Differentially expressed miRNAs were identified using Significant Analysis of Microarrays (SAM) algorithm, by using the two-class (unpaired) format, not considering equal variances. 25 Significant genes were selected based on false discovery ratio and controlling the q-value for the gene list. To estimate whether a given group of MM patients were significantly associated with a set of miRNAs, a Global Test algorithm was used. 26 This method is based on a prediction model for predicting a response variable from the expression measurements of a set of bioentities. The null hypothesis to be tested is that the expression profile of the miRNAs set selected is not associated with the samples. If the null hypothesis were true, then the expected influence parameter should be 0. The Global Test algorithm used in this study corresponds to its version in R, a package called globaltest.
mRNA gene expression profiling
RNA labeling and microarray hybridization have been previously reported. 27 Briefly, 100-300 ng of total RNA were amplified and labeled using the WT Sense Target labelling and control reagents kit (Affymetrix, Santa Clara, CA, USA), and then hybridized to Human Gene 1.0 ST Array (Affymetrix). Washing and scanning were carried out using GeneChip System of Affymetrix (GeneChip Hybridization Oven 640, GeneChip Fluidics Station 450 and GeneChip Scanner 7G). Full microarray data compliant with the MIAME guidelines (http://www.mged.org/) are available at the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/, accession number GSE16558). Expression value for each probe set was calculated using RMAExpress program that uses RMA (Robust Multi-Array Average) algorithm. 28 A differential expression analysis was carried out on the data using SAM algorithm to identify genes with statistically significant changes in expression between different classes.
miRNA target prediction and correlation with gene expression
Target prediction was carried out using miRecords, an integrated resource for animal miRNA-target interactions. 29 The Predicted To identify the putative mRNA targets of the significant miRNAs, which at the same time were selected as significantly deregulated genes in the class comparison analysis of geneexpression data, as well as to look for associations between intronic miRNAs and host genes, a Pearson correlation analysis was carried out using a cutoff p-value o0.05 (two-tailed). Calculation of the p-values assigned to the Pearson's correlation coefficients was done assuming that the variables follow a bivariate normal distribution.
Even after extensive studies, it is not well known what makes that an mRNA follows the cleavage or translational repression pathway. There are experimental analyses which support the presence of specific molecular requirements that can contribute to a preferential degradation of the messages after introducing a miRNA. 30 On the basis of that we have used four programs (TargetScan 5.1; miRDB; miRanda; and Pictar) which, in addition to consider the perfect complementarity between miRNA and mRNA in the 'seed' region, also use for predictions the following requirements: 3 0 region pairing, conservation of the site, untranslated region (UTR) context, number of sites and free energy of the complex. To eliminate the probable false-positive predictions, we have recognized, as probably leading to mRNA degradation, only those miRNA-mRNA pairs that were predicted by at least three programs. The mRNA databases or the versions of the same mRNA database may be different in each program. Occasionally, it can then occur that the sequences of some genes were not present in a database, so the prediction of miRNA target could not be carried out. Only in these cases we considered those genes as probable targets that were predicted by two programs. To further eliminate the possibility of false-positive predictions we have chosen only these predictions that had simultaneously prediction score higher than: À0.3 for TargetScan; 60 for miRDB; 2 for Pictar and 150 for miRanda. Detailed information about prediction criteria of every program is included in the Supplementary Methods.
The functional analysis to identify the most relevant functional categories in the datasets of miRNA target genes selected by statistical analysis was generated through the use of Ingenuity Pathways Analysis (Ingenuity Systems, Mountain View, CA, USA). To analyze the effect of target genes on biology of multiple myeloma we have analyzed the molecular function of each gene. To do this we have searched subsequent databases: Entrez, GeneCard, UniProtKB/SwissProt and KEGG.
Results
Unsupervised analysis of miRNA expression
Initially, we investigated the miRNA expression data set using unsupervised analysis. A two-dimensional clustering analysis carried out on the filtered data revealed that the MM samples were not distributed into clearly separated clusters according to chromosomal abnormalities. Nevertheless, the four samples with t(14;16) were tightly clustered, and MM with t(4;14) and those with RB deletion showed a trend to be segregated into the same subclusters (Supplementary Figure 1) .
miRNAs differentially expressed in the cytogenetic subtypes of myeloma
It is well-known that subtle differences in gene expression among closely related neoplastic subtypes may escape detection using unsupervised clustering analysis, whereas supervised methods can detect them. Therefore, in a supervised approach, we looked for miRNAs significantly deregulated in the different cytogenetic subtypes of MM compared with normal PC. For this purpose, we used the SAM algorithm with an false discovery rate (FDR) o0.001 in all class comparisons. As compared with normal PC, we identified 11, 8, 7, 37 and 18 miRNAs differentially expressed in MM cells from patients with t(4;14), t(14;16), t (11;14) , RB deletion as a unique abnormality and cytogenetically normal MM samples, respectively. Significantly deregulated miRNAs with their chromosomal band location, in the different cytogenetic subsets are presented in Table 2 . Only miR-214 and miR-375 were commonly deregulated in these five comparisons (both being underexpressed). A previous report has described that the inhibition of mir-214 was associated with decreased apoptosis in HeLa cells. 31 The 11 miRNAs significantly deregulated in MM cells with t(4;14) were downregulated compared with normal PC. miRNA-203 and miRNA-342 were located at 14q32, but they were not clustered together. Similarly, using the same restrictive FDR, the seven miRNAs deregulated in MM patients with t(11;14) were also underexpressed. Those patients with t(14;16) showed a singular signature characterized by the underexpression of five miRNAs and the overexpression of three miRNAs. It is noteworthy to mention, that miR-1 and miR-133a, both upregulated in MM with t(14;16), were clustered on the same chromosomal locus at 18q11 (Figure 1 ). When we compared the expression of these two miRNAs in MM with t(14;16) with their expression in the other cytogenetics groups we observed that these miRNA were overexpressed only in the four cases with t(14;16) ( Figure 2 ).
All the miRNAs deregulated in patients with RB deletion compared with normal PC samples were infra-expressed and interestingly, the miR-20a, miR-19b, miR-15a and miR-19a, were located in 13q. Furthermore, these miRNAs were not significantly downregulated in the other genetic subtypes. We confirmed this finding when we compared the miRNA expression between MM patients with only RB deletion and MM patients without this abnormality. Among the set of 8 miRNAs downregulated in the samples with RB deletion, miR-20a, miR18a and miR-19b, located at 13q31, were included. The reason why the other miRNAs localized in 13q, such as miR-16-1 at 13q14, as well as miR-622 at 13q31, were not infra-expressed in our study is unknown, but differences in PCR efficiency due to highly multiplexed pools in the reverse transcription reaction cannot be excluded from consideration.
In this series we also included 13 patients with normal fluorescence in situ hybridization (FISH) analysis, which displayed a particular miRNAs signature characterized by the downregulation of 18 miRNAs. Mir-362 and miR-501 were clustered together at Xp11. We failed to find a specific miRNA expression profile for MM cases with 1q gains or P53 deletion. Probably, their association with other abnormalities, such as t(4;14) and RB deletion, prevents the identification of miRNA exclusively deregulated in MM with these abnormalities. Nevertheless, clustering analysis of MM with t(4;14) and MM with RB deletion did not segregate samples according to 1q status.
When we applied the Global Test algorithm to all the MM samples (the only sample with monosomy 13 and P53 deletion was not considered) using the 49 miRNAs found significative (miRNAs duplicated in the different MM subgroups were eliminated), the different groups of samples agreed with the miRNAs signature and they provided a positive 'influence' in such signature. The MM subtype that had higher average influence in the signature was that with t(14,16) and the one that microRNAs in myeloma NC Gutiérrez et al had lower influence was the normal FISH subgroup (Figure 3) .
We also compared miRNA expression in the total 60 MM samples with that of normal PC using SAM analysis, and we found 11 miRNAs downregulated in MM patients: miR-375, miR-650, miR-214, miR-135b, miR-196a, miR-155, miR-203, miR-95, miR-486, miR-10a and miR-196b.
Relationship between miRNA and mRNA expression profiling
In addition to the miRNA expression analysis, protein-coding gene expression profiling was carried out for all the MM samples using high-density oligonucleotide microarrays. miRNAs were believed to act mainly by interfering translation rather than reducing the expression levels of the target mRNAs. However, there are studies indicating that the expression regulation at the mRNA level may be a common mechanism for miRNA regulation. 32 Moreover, there is increasing evidence supporting that the simultaneous profiling of mRNA, by using microarrays, and miRNA is an effective strategy for aiding in the detection of functional miRNA targets. [33] [34] [35] Accordingly, we combined our miRNA and mRNA expression data sets in order to find deregulated genes than can be specific targets of the miRNAs forming the signature of each MM cytogenetic group. First, we identified those genes with statistically significant changes in the expression between different cytogenetic subclasses of MM and normal PC using SAM algorithm with a cutoff FDR p0.03. Second, we searched for putative target genes for each significant miRNA using miRecords database, selecting only those target gene transcripts proposed by at least 5 of 11 established miRNA target prediction programs. In a further step, we selected the intersection between miRNA target genes Table 2 Deregulated microRNAs (miRNAs) in each of the cytogenetic groups in comparison with normal plasma cell (NPC); all the miRNAs were downregulated except for miR-1, miR-449 and miR-133a, which were upregulated in multiple myeloma (MM) with t (14;16 respectively. Most of the predicted miRNA target genes for the miRNA characterizing MM with t(4;14) and MM with t(14;16) were assigned to the functional categories of cellular growth and proliferation: JUND, MYBL1, SOCS3, CCND2, SLC7A5 and IRAK1 upregulated in MM with t(4;14), and AKAP12, CREG1, EEF2K, IGFBP5, RASSF5, S1PR1, TFAP2C, WNT5A and CCND2 upregulated in MM with t(14;16). This observation suggests a possible link between the miRNA downregulation in these MM subsets and an advantage in myeloma cell growth. The majority of candidate miRNA target genes inversely correlated with miRNA signature of MM with monosomy 13 were involved in cell death category in the functional analysis.
Although the analysis strategy up to this point was based on target gene selection from at least five miRNA-target prediction programs and on a further inverse correlation, filters for discriminating those miRNA-mRNA interactions more susceptible to a degradation process were not applied. Therefore, we carried out a final step in the bioinformatic analysis selecting stringent criteria filters from the combination of four programs, including criteria of seed region complementarity and UTR context, which greatly reduces false-positive predictions and provide miRNA-mRNA interactions potentially more sensitive to a cleavage pathway. 20, 30, 34 The miRNA target genes selected using this more accurate analysis approach are shown in Tables  3 and 4. A significant number of miRNAs are located within the intronic regions of either coding or non-coding transcription units. The expression of intronic miRNA is believed to be regulated by the expression of the host mRNA. 36 In this study, we selected the intronic miRNAs among the deregulated miRNAs, in order to investigate whether their host genes were also deregulated in the MM gene expression profile. However, we did not find any significant correlation between the intronic miRNAs and their host transcripts.
Discussion
In this study, a genome-wide miRNA expression profiling on MM samples with different cytogenetic abnormalities was carried out. Our results show that the genetic subgroups in MM are associated with singular miRNA signatures. Supervised approaches identified miRNA sets differentially expressed in the MM genetic groups, although not clearly separated clusters containing specific cytogenetic abnormalities were observed. The fact that genetic subgroups were not distinguishable in the miRNA clustering is in contrast to the studies in acute lymphoid and myeloid leukemias, wherein miRNA expression grouped samples according to the genetic rearrangements. It is possible that the complexity of the genetic portrait of myeloma cells with multiple associations of genetic abnormalities within the same cell as compared with that of myeloid and lymphoid blasts, may explain the inability to segregate MM cytogenetic subgroups by miRNA unsupervised clustering. 12, 37, 38 In fact, there is a strong association between the different genetic abnormalities in MM, particularly between t(4;14) and RB deletion and 1q gains. 1 One of the most significant findings was the upregulation of miR-1 and miR-133a, belonging to a cluster at 18q11, in MM with t(14;16). These two miRNAs have distinct roles in modulating skeletal and cardiac muscle proliferation and differentiation, and their potential function in the MM with t(14;16) deserves further investigation. 39 With respect to the MM samples harboring RB deletion, the underexpression of miRNAs located in 13q would reflect a reduction in dosage of these miRNAs as a consequence of monosomy 13, since in most MM cases RB deletion detected by FISH represents whole chromosome monosomy. This observation is in agreement with the haploinsufficiency of many of the genes mapped at chromosome 13, demonstrated by gene expression analysis. 40 
Table 3
Potential microRNA (miRNA)-mRNA interactions deregulated in the multiple myeloma (MM) with immunoglobulin heavy-chain gene (IGH) translocations None of the 11 miRNAs downregulated in the total 60 MM samples has been related to lymphoid cells except for miR-155, which participates in B-cell differentiation and could act as a tumor suppressor by reducing potentially oncogenic translocations generated by AID gene. 41 It has also been demonstrated that the failure of miR-155-deficient B cells to generate highaffinity switched antibodies appears not because of a defect in somatic hypermutation or class-switch recombination, but more likely to a defect in the differentiation or survival of plasmablasts. 42 The predominance of infra-expressed miRNAs in myeloma samples is consistent with the global decrease in miRNA levels observed in other human cancers. 37, 43, 44 Nevertheless, Pichiorri et al.
14 have recently reported distinctive miRNA signatures in MM and MGUS characterized mainly by the overexpression of miRNAs. Moreover, the deregulated miRNAs are not the same in the two studies. There are some plausible explanations for these discrepancies. First, the platforms used for miRNA analysis were different and there are around 110 miRNAs only explored by one of the two approaches; second, the number of primary myelomas analysed in this study is higher and the samples are selected according to the genetic abnormalities, whereas the genetic status of MM samples from Pichiorri's study is unknown; and at last, the statistical design in terms of class comparisons and significance level is also different.
miRNA target prediction remains a major bioinformatic challenge, particularly because of false-positive predictions. In this study, we combined several strategies to identify miRNAmRNA interactions more susceptible to a degradation process. Using these stringent criteria, we found that the miR-135b and miR-146a (Table 3) , both downregulated in MM with t(4;14), targeted two genes (PELI2 and IRAK1) involved in IL-1 signalling Table 4 Potential microRNA (miRNA)-mRNA interactions deregulated in the multiple myeloma (MM) with monosomy 13 as a unique abnormality pathway, which is a potent inducer of IL-6. IRAK1 (IL-1 receptor-associated kinase) activates and recruits TRAF6 to the IL-1 receptor complex, 45, 46 and PELI2 is a scaffold protein probably involved in the IL-1 signalling through its interaction with the complex containing IRAK kinases and TRAF6. 47 Both IRAK1 and PELI2 display two matches to the miR-146a and miR-135b respectively, which increases the prediction specificity. In addition, IRAK1 is a validate target of miR-146a. 48, 49 Concerning MM with t(14;16) four genes (GPD2, GLCCI1, FNDC3B and ASH2L) were targeted by miR-1 (Table 3) . A role in cancer has been reported for all of them, although an involvement in myeloma biology has not been found. Among the potential miRNA-mRNA interactions detected in MM patients with monosomy 13, it should be noted that miR-19a and miR-19b, belonging the miR-17B92 cluster, target the overexpressed IGF1 transcript (Table 4) . Likewise, MAPK6 is targeted by three of the miRNAs downregulated in MM with monosomy 13 (miR-19a, miR-let-7b and miR-374a). As MAPK route and IGFR1 pathway have important roles in the control of MM cell biology, the investigation of these miRNAs interactions would be interesting. 50, 51 When we applied this stringent approach to the 11 miRNAs deregulated in all MM comparing with normal PC no predicted miRNA-mRNA interactions fulfilled the filters, but miR-10a and its predicted target BACH2, and miR-135b and its putative target CD47 were very close to the established thresholds. The transcription factor BACH2, together with other factors such as BLIMP1 appears to constitute a main transcriptional regulatory network for the terminal differentiation of B cells to PC. 52 CD47 is an integrin-associated protein which modulates cell activation and adhesion. 53, 54 Our group has reported that CD47 upregulation is only present in PC from MM, but not in PC from Waldenstrom's macroglobulinemia. 55 The potential role of miR-10a and miR-135b in the CD47 and BACH2 expression deserves to be explored.
It is interesting to note that CCND2, which was upregulated both in MM subtypes t(4;14), t(14;16) and monosomy 13, have target sites for several miRNA significantly deregulated in these cytogenetic subtypes. It has been proposed that dysregulation of a CYCLIN D gene is a unifying oncogenic event in MM. 5 About 45% of MM express CCND2, particularly those MM with t(14;16) and t(4;14). However, the mechanism responsible for the increased expression of CCND2 in MM often remains unknown. Therefore, it could be speculated that the underexpression of miR-196b, miR-135b, miR-320, miR-20a, miR-19b, miR-19a and miR-15a found in many MM (see Supplementary Tables) could contribute to the overexpression of their predicted target CCND2. Noteworthy, miR-15a and miRNA-19a were the only ones selected using the stringent analysis and displayed three and two sites in the 3 0 UTR (Table 4) . These results are supported by a recent study, which demonstrates that the transfection of myeloma cells with the pre-miRNA-15a results in CCND2 inhibition. 15 Unfortunately, although the presence of perfect seed pairing and other bioinformatic criteria predict miRNA regulation more likely led to mRNA degradation, false positives cannot be ruled out. On the other hand, the possibility that there are additional redundant indirect pathways also contributing to their degradation should be kept in mind. Hence the functional characterization of the results obtained by using bioinformatic analysis is of paramount importance.
In summary, these results indicate that miRNA expression is deregulated in myeloma cells, and what is more important, that the miRNA pattern of expression in MM seems to be associated with specific genetic abnormalities. Of particular interest is our finding of the upregulation of the cluster miR-1/miR-133a in MM samples with t(14;16), which supports a role for miRNAs in the pathogenic pathways of MM putatively delineated by chromosomal aberrations. In addition, the strategy proposed of finding potential miRNA-mRNA interactions could be useful to identify relevant protein-coding genes in MM pathogenesis that can be regulated by miRNAs.
